New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
10:29 EDTSPPIFDA approves Beleodaq for treatment of patients with PTCL
The FDA approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma, PTCL, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. Beleodaq and Folotyn are marketed by Spectrum Pharmaceuticals (SPPI).
News For SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SPPI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use